Jardiance gets parity with Farxiga in US as FDA clears use in heart failure

Jardiance gets parity with Farxiga in US as FDA clears use in heart failure

Submitted by admin on August 18, 2021 - 11:43pm
Source: 
Pharmaforum
News Tags: 
Eli Lilly
Boehringer Ingelheim
FDA
diabetes
Jardiance
heart failure with reduced ejection fraction
Headline: 
Jardiance gets parity with Farxiga in US as FDA clears use in heart failure
snippet: 

Eli Lilly and Boehringer Ingelheim have claimed FDA approval for their diabetes therapy Jardiance in heart failure with reduced ejection fraction (HFreF), setting up a market tussle with AstraZeneca’s Farxiga.

Do Not Allow Advertisers to Use My Personal information